Wilmington Savings Fund Society FSB Purchases 3,294 Shares of Danaher Corporation $DHR

Wilmington Savings Fund Society FSB lifted its position in Danaher Corporation (NYSE:DHR) by 6.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 52,624 shares of the conglomerate’s stock after purchasing an additional 3,294 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Danaher were worth $10,433,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. White Pine Capital LLC boosted its stake in Danaher by 1.4% in the second quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock worth $690,000 after buying an additional 49 shares in the last quarter. Boyd Watterson Asset Management LLC OH boosted its stake in shares of Danaher by 2.1% in the 2nd quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock valued at $499,000 after purchasing an additional 51 shares in the last quarter. Worth Financial Advisory Group LLC boosted its position in Danaher by 4.6% during the second quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after buying an additional 53 shares during the period. Howard Capital Management Group LLC grew its stake in shares of Danaher by 4.8% during the third quarter. Howard Capital Management Group LLC now owns 1,159 shares of the conglomerate’s stock valued at $230,000 after buying an additional 53 shares during the last quarter. Finally, American National Bank & Trust increased its holdings in shares of Danaher by 2.3% in the third quarter. American National Bank & Trust now owns 2,451 shares of the conglomerate’s stock worth $486,000 after buying an additional 54 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. The trade was a 59.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Teri List sold 3,298 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the transaction, the director directly owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. This trade represents a 13.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 30,248 shares of company stock valued at $6,609,663 over the last quarter. Corporate insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of analyst reports. KeyCorp reaffirmed an “overweight” rating on shares of Danaher in a research note on Thursday, December 18th. Morgan Stanley started coverage on shares of Danaher in a research note on Monday, December 1st. They issued an “overweight” rating and a $270.00 target price on the stock. Redburn Partners set a $220.00 price target on shares of Danaher in a report on Wednesday, October 8th. Bank of America cut their price target on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Finally, Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Twenty-one analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $250.96.

Danaher Trading Up 0.8%

DHR opened at $239.83 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $258.23. The stock has a market cap of $169.40 billion, a PE ratio of 49.45, a PEG ratio of 4.23 and a beta of 0.89. The business has a 50 day moving average of $227.79 and a 200-day moving average of $211.58.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The business had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.71 earnings per share. Equities research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Friday, December 26th. Danaher’s dividend payout ratio (DPR) is 26.39%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.